Attached files
file | filename |
---|---|
EX-10.1 - EXECUTIVE EMPLOYMENT AGREEMENT - Medite Cancer Diagnostics, Inc. | ex10-1.htm |
8-K - FORM 8-K - Medite Cancer Diagnostics, Inc. | mdit8k_apr272017.htm |
Exhibit 99.1
MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial
Officer
Orlando, Fl., April 27, 2017 -MEDITE Cancer Diagnostics,
Inc., (OTCQB: MDIT) (the “Company”) specializing in the
development, manufacturing, and marketing of molecular biomarkers
and premium medical devices for detection, risk assessment and
diagnosis of cancer and precancerous conditions, today announced
the appointment of Susan Weisman as Chief Financial
Officer
“MEDITE
has worked with Susan in her role as an independent consultant
since March of 2016. We believe Susan’s past results and
experience can assist MEDITE in building the infrastructure for
substantial growth in the United States, Germany and worldwide. We
also believe Susan’s extensive knowledge, experience and
diverse industries background will be important for the Company to
improve its infrastructure, reporting and relationships with the
financial community,” says David Patterson CEO.
“I
am excited about the future of the Company as we look to
substantially grow our business globally, launch our new world
class products as more efficient and cost effective solutions in
the detection of cancer and cancer related diseases. I also look
forward to working with the team at MEDITE,” says Susan
Weisman, newly appointed CFO of MEDITE Cancer Diagnostics,
Inc.
Susan
Weisman a Financial Executive focused on operations, financial
reporting, treasury management and strategic planning and cost
controls during her 30 year career with Mitsui & Co (USA),
BankAtlantic Bancorp and various other companies will become the
Chief Financial Officer of MEDITE Cancer Diagnostics,
Inc.
About MEDITE Cancer Diagnostics, Inc.
MEDITE
Cancer Diagnostics Inc., is a Delaware registered company
consisting of wholly-own MEDITE GmbH a Germany-based company with
its subsidiaries. On April 3, 2014, MEDITE was acquired by former
CytoCore, Inc. a biomolecular diagnostics company engaged in the
design, development, and commercialization of cost-effective cancer
screening systems and Biomarkers to assist in the early detection
of cancer. By acquiring MEDITE the company changed from solely
research operations to an operating company with a well-developed
infrastructure, approximately 80 employees in four countries, a
distribution network to about 80 countries worldwide, a well-known
and established brand name and a wide range of products for
anatomic pathology, histology and cytology
laboratories.
Forward Looking Statement
This press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
regarding future operating performance, events, trends and plans.
All statements other than statements of historical fact contained
herein, including, without limitation, statements regarding our
future financial position, business strategy, budgets, projected
revenues and costs, and plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as “may,”
“will,” “expects,” “intends,”
“plans,” “projects,”
“estimates,” “anticipates,” or
“believes” or the negative thereof or any variation
thereon or similar terminology or expressions. We have based these
forward-looking statements on our current expectations and
projections about future events. These forward-looking statements
are not guarantees and are subject to known and unknown risks,
uncertainties and assumptions about us that may cause our actual
results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity,
performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause our
actual results to differ from our expectations, include but are not
limited to, MEDITE’s ability to maintain and grow its
revenues. Readers are cautioned not to place undue reliance on our
forward-looking statements, as they speak only as of the date made.
Such statements are not guarantees of future performance or events
and we undertake no obligation to disclose any revision to these
forward-looking statements to reflect events or circumstances
occurring after the date hereof.
For more information please visit: www.medite-group.com
Investor Contact:
David Patterson CEO
317-341-3589